TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00451295
Drug: MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
Study: NCT00451295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
Study: NCT02351908
Drug: Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02351908
Drug: Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02351908
Drug: Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04319081
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are included after PCSK9 inhibitors prescription , at the first dispensation
Study: NCT02775877
Drug: HMG
Normalized name: HMG-CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003152
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03634436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous
Study: NCT02872857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will match drug capsules.
Study: NCT05901350
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Some patients did not reduced the dose of levodopa after STN-DBS comparing to some without reducing the dose.
Study: NCT03675295
Drug: Hyalase
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
Study: NCT00035295
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01671150
Drug: endotoxin
Normalized name: Endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
Study: NCT01311518
Drug: Drug: Injectable Thymosin beta 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable administration of Thymosin Beta 4 by intravenous bolus at 1200 mg, or 450 mg daily for 3 days then weekly for 4 consecutive weeks
Study: NCT01029704
Drug: Placebo capsules to match EGT0001442
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Segment 1: Not applicable.~Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days.
Study: NCT00002701
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002701
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002701
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002701
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02068170
Drug: Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00219570
Drug: clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00419601
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h
Study: NCT02395640
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 po d1-14
Study: NCT00559299
Drug: GSK163090
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00674466
Drug: 1.5 mg or 2.0 mg CJC-1134-PC
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice-a-week
Study: NCT00674466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice-a-week
Study: NCT02273375
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02273375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03408470
Drug: [14C]-TD-1473 IV bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Intervention description included in arm description)
Study: NCT03408470
Drug: [14C]-TD-1473 Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Intervention description included in arm description)
Study: NCT00003764
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00438100
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
Study: NCT02339116
Drug: fluoruracil
Normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02316899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily
Study: NCT04560283
Drug: Vaginal gel HYALOGYN®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel HYALOGYN® (HYDEAL-D® 2%; Fidia Farmaceutici, Abano Terme, Italy) every 3 days up for 12 consecutive weeks
Study: NCT02733731
Drug: Chinese Herbal Compound Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02733731
Drug: Estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02280759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo consists of an identical formulation, except active substance
Study: NCT02134626
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg / pill, one pill orally once a day for three months
Study: NCT02134626
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01655082
Drug: V0116 transdermal patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: One patch per day (during 24 hours) for 21 days
Study: NCT02350946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03540303
Drug: CAR19 T cells carrying cytoplasmic activated PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: step 1: Collect 50-100ml of peripheral blood for culture of CAR19 T cells carrying cytoplasmic activated PD-1 step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 2x106 /kg for the first 3 patients, 6x106 /kg for the second 3 patients and 18x106 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy.
Study: NCT03633799
Drug: VeraCept
Approvals — FDA: no, EMA: no, PMDA: no
Description: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method
Study: NCT00078832
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arimidex placebo
Study: NCT00101075
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02122770
Drug: MLN4924
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN4924 intravenous solution.
Study: NCT00483106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: taken orally twice a day for 7 consecutive days
Study: NCT00904085
Drug: Oxymorphone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg
Study: NCT00380081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sublingual tablet administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
Study: NCT00132938
Drug: telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02345460
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02345460
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02280616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet twice daily AND 5ml placebo suspension twice daily
Study: NCT02048917
Drug: High Intensity Counseling + Long Acting NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Intensity Counseling + Long Acting NRT
Study: NCT02048917
Drug: Low Intensity Counseling + Long Acting NRT + PRN NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Intensity Counseling + Long Acting NRT + PRN NRT
Study: NCT02048917
Drug: Low Intensity Counseling + Long Acting NRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Intensity Counseling + Long Acting NRT
Study: NCT02309892
Drug: L-DOS47
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: A treatment cycle will be 21 days, with patients receiving L-DOS47 on cycle Days 1, 8, and 15 and pemetrexed/carboplatin on Day 1 of each treatment cycle.
Study: NCT00721344
Drug: Technosphere Inhalation Powder (FDKP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere® Inhalation Powder 20mg
Study: NCT00721344
Drug: Technosphere Inhalation Powder (FDKP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere® Inhalation Powder 40mg
Study: NCT00721344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cartridges
Study: NCT03026140
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib will be administered starting day 1 until 1 day before surgery daily (if patient is randomized to group 2 (only applicable for patients with a MSS tumor)
Study: NCT00336024
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00336024
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or orally
Study: NCT00336024
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00947661
Drug: SPARC0912
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drops, once daily, 12 weeks
Study: NCT00947661
Drug: Reference0912
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drops, once daily, 12 weeks
Study: NCT01317797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered three times, subcutaneous in the abdomen
Study: NCT02339129
Drug: SST-0225
Approvals — FDA: no, EMA: no, PMDA: no
Description: SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
Study: NCT02339129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
Study: NCT00500604
Drug: Irbesartan/hydrochlorothiazide
Normalized name: irbesartan/hydrochlorothiazide 300 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/12.5mg tablet and 300/12.5mg tablet
Study: NCT00500604
Drug: Valsartan/hydrochlorothiazide
Normalized name: valsartan/hydrochlorothiazide 160 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80/12.5mg tablet and 160/12.5mg tablet
Study: NCT04506905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets of dose-matched placebo to MK-8189 according to randomization
Study: NCT02957968
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 once every 2 weeks for 4 cycles.
Study: NCT02957968
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.
Study: NCT00003364
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003364
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03847727
Drug: BR as Maintenance
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of the study group who have achieved at least a partial response after 6 cycles of BR induction will receive additionally 4 cycles of BR every 3 months as maintenance therapy.
Study: NCT02216084
Drug: Recombinant ADAMTS13
Normalized name: ADAMTS13, recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.~Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3).
Study: NCT01209078
Drug: GSK1322322
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1322322 1500mg BID
Study: NCT01209078
Drug: GSK1322322 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03070899
Drug: OBE2109
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBE2109 100mg tablets for oral administration once daily
Study: NCT03070899
Drug: Placebo to match OBE2109
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match OBE2109 100mg tablets for oral administration once daily
Study: NCT03070899
Drug: Placebo to match Add-back
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
Study: NCT01266590
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02782260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01170637
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg oral administration (RhinAdvil(R))
Study: NCT01170637
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg oral administration (BI product)
Study: NCT01968356
Drug: 3M CHG/IPA Prep Colorless
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically.
Study: NCT01601457
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
Study: NCT02253966
Drug: Methylprednisoloneacetate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04316494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match Hydroxychloroquine.~Excipients:~Microcrystalline cellulose Lactose Magnesium Stearate
Study: NCT03676114
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same volume of normal saline will be administrated
Study: NCT03842839
Drug: Salbutamol sulphate aerosol (Ventolin) 0.01mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: As needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens
Study: NCT01240980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, Oral, 0 mg, once daily, 1 day
Study: NCT01240980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension, Oral, 0 mg, once daily, 1 day
Study: NCT01240980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension using crystalline form, Oral, 0 mg, once daily, 1 day
Study: NCT02347891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized phase: Week 0 - Week 40
Study: NCT00538044
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
Study: NCT00070135
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02947438
Drug: EPREX®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Study: NCT02947438
Drug: EPIAO®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Study: NCT04318158
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single shot US guided TAP block using 20 ml bupivacaine 0.25% + 50 µg fentanyl on each side.
Study: NCT00878969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02056106
Drug: antidepressant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00524914
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo subcutaneous
Study: NCT01592162
Drug: propofol 1% (Astra-Zeneca) and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
Study: NCT01592162
Drug: propofol 1% (Astra-Zeneca) and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
Study: NCT01592162
Drug: Propofol (Astra-Zeneca) and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
Study: NCT01592162
Drug: Propofol (Astra-Zeneca) and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
Study: NCT01592162
Drug: Propofol (B-Braun) and remifentanil
Normalized name: DISPENSING PIN B BRAUN #415072
Approvals — FDA: no, EMA: no, PMDA: no
Description: propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
Study: NCT03373058
Drug: adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group.
Study: NCT01722097
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01896609
Drug: Bon one in Arm 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 3 , Bon One ® 0.5 µg daily orally for 48 weeks
Study: NCT01896609
Drug: Xerovirinc in Arm 2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks
Study: NCT02946814
Drug: essential oils
Normalized name: essential oils
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00651599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
Study: NCT03207906
Drug: VBP-926
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical VBP-926 solution
Study: NCT03441607
Drug: mHACMb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredient
Study: NCT03404726
Drug: BAY2402234
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY2402234 is a potent and selective small molecule inhibitor of dihydroorotate dehydrogenase. A solution of BAY2402234 will be available to initiate the trial and there are plans to transition to a tablet form of BAY2402234 once it becomes available. Both liquid and tablet formulations of BAY2402234 will be continually administered once daily by mouth in 28 day cycles.
Study: NCT03188068
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administered with sirolimus
Study: NCT04281901
Drug: Platelet- and extracellular vesicle-rich plasma
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: ear wick soaked in platelet- and extracellular vesicle-rich plasma
Study: NCT04281901
Drug: Standard conservative treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard conservative measures, including antimicrobials, antiseptics and aural toilette for treating a chronically inflamed radical cavity.
Study: NCT03495739
Drug: RDG-17012 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran Etexilate tosylate 150mg
Study: NCT02971475
Drug: Analgesics
Normalized name: ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
Study: NCT03363451
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observation study, no specific antibiotics will be indicated during treatment